Nuclear magnetic resonance–determined lipoprotein abnormalities in nonhuman primates with the metabolic syndrome and type 2 diabetes mellitus

Metabolism ◽  
2007 ◽  
Vol 56 (6) ◽  
pp. 838-846 ◽  
Author(s):  
Shi-Ying Ding ◽  
Xenia T. Tigno ◽  
Barbara C. Hansen
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Nuclear Magnetic Resonance ◽  
Type 2 Diabetes Mellitus ◽  
Magnetic Resonance ◽  
Nonhuman Primates ◽  
The Metabolic Syndrome ◽  
Nuclear Magnetic

scholarly journals Lower Plasma Magnesium, Measured by Nuclear Magnetic Resonance Spectroscopy, is Associated with Increased Risk of Developing Type 2 Diabetes Mellitus in Women: Results from a Dutch Prospective Cohort Study

2019 ◽  
Vol 8 (2) ◽  
pp. 169 ◽  
Author(s):  
Joëlle C. Schutten ◽  
António W. Gomes-Neto ◽  
Gerjan Navis ◽  
Ron T. Gansevoort ◽  
Robin P.F. Dullaart ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Nuclear Magnetic Resonance ◽  
Type 2 Diabetes Mellitus ◽  
Magnetic Resonance ◽  
Inverse Association ◽  
Increased Risk ◽  
Study Results ◽  
Nuclear Magnetic

Background: Low circulating magnesium (Mg) is associated with an increased risk of developing type 2 diabetes mellitus (T2DM). We aimed to study the performance of a nuclear magnetic resonance (NMR)-based assay that quantifies ionized Mg in EDTA plasma samples and prospectively investigate the association of Mg with the risk of T2DM. Methods: The analytic performance of an NMR-based assay for measuring plasma Mg was evaluated. We studied 5747 subjects free of T2DM at baseline in the Prevention of Renal and Vascular End-stage Disease (PREVEND) study. Results: Passing–Bablok regression analysis, comparing NMR-measured ionized Mg with total Mg measured by the Roche colorimetric assay, produced a correlation of r = 0.90, with a slope of 1.08 (95% CI: 1.00–1.13) and an intercept of 0.02 (95% CI: −0.02–0.08). During a median follow-up period of 11.2 (IQR: 7.7–12.0) years, 289 (5.0%) participants developed T2DM. The association of NMR-measured ionized Mg with T2DM risk was modified by sex (Pinteraction = 0.007). In women, we found an inverse association between Mg and the risk of developing T2DM, independent of adjustment for potential confounders (HR: 1.80; 95% CI: 1.20–2.70). In men, we found no association between Mg and the risk of developing T2DM (HR: 0.90; 95%: 0.67–1.21). Conclusion: Lower NMR-measured plasma ionized Mg was independently associated with a higher risk of developing T2DM in women, but not in men.

scholarly journals Advantages of therapy with sodium glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus in combination with hyperuricemia and gout

2020 ◽  
Vol 92 (5) ◽  
pp. 110-118 ◽  
Author(s):  
T. S. Panevin ◽  
M. S. Eliseev ◽  
M. V. Shestakova ◽  
E. L. Nasonov
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Type 2 Diabetes Mellitus ◽  
New Drugs ◽  
Positive Effects ◽  
The Metabolic Syndrome ◽  
Sodium Glucose Cotransporter ◽  
The Russian Federation

Currently, only two drugs for reducing uric acid (UA), allopurinol and febuxostat, are registered in the Russian Federation, but their use does not allow to achieve the target level of UA in all cases. According to the results of numerous randomized trials, hyperuricemia and gout are associated with the corresponding components of the metabolic syndrome, including diabetes mellitus. The influence of factors is due to the need to search for new drugs that have a complex effect on several components of metabolic syndrome at once. Potentially attractive in this regard is a new group of drugs for the treatment of type 2 diabetes mellitus inhibitors of the sodium-glucose cotransporter of type 2, which, in addition to the main hypoglycemic actions, showed positive effects on the cardiovascular system, kidneys, as well as lowering UA.

Sign in / Sign up

Export Citation Format

Share Document